NCT07035197Completed
Facilitators and Barriers to Eptinezumab Administration in Thailand
Facilitators and Barriers to Eptinezumab Administration in Thailand: Real-World Experiences and Perspectives From Mixed-method Design and In-Depth Interviews (FACEpi)
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This research study is designed as a longitudinal prospective descriptive study using mixed-method data collection. Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody (anti-CGRP mAb), is administered by intravenous (IV) infusion every 3 months as preventive medication for individuals with migraine who have been diagnosed based on theInternational Classification of Headache Disorders, 3rd edition (ICHD-3) by headache specialist neurologists. The goal of this study is to understand the real-life experiences of people with migraine who receive eptinezumab in a hospital setting in Thailand, a middle-income country. The researchers want to learn about what makes it easier or harder for patients and healthcare workers to use this treatment. The main questions it aims to answer are: * What are the barriers and facilitators to using eptinezumab from the perspectives of patients and healthcare providers? * Does eptinezumab reduce monthly migraine days and improve quality of life over time? Participants will: * (For migraine patients) Take part in an in-depth interview (IDI) within 24 hours after receiving an eptinezumab infusion * (For migraine patients) Complete questionnaires about migraine symptoms, disability, and quality of life at baseline, 3 months, and 6 months * (For healthcare providers) Take part in a one-time interview about their experiences administering eptinezumab The study will also look at how well eptinezumab works by measuring changes in monthly migraine days and other health scores over a 6-month period. The information from this study may help improve migraine care in Thailand and support better access to new treatments like eptinezumab.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 3 Jun 2025
- Start date
- 25 Aug 2025
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Chulalongkorn University
- Diseases
- Migraine
- NCT number
- NCT07035197
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 25 Aug 2025 to the primary completion date, 31 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Target Population
- Group 1: Patients who were diagnosed migraine with or without aura or chronic migraine and have received eptinezumab.
- Group 2: Healthcare providers (e.g. doctor, outpatient nurse and daycare nurse) who are responsible for providing eptinezumab to the patients.
- Inclusion Criteria Group 1: People with migraine with or without aura or chronic migraine Inclusion criteria Group 1A
- Age ≥ 18 years
- Diagnosed with migraine with or without aura or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\*
- Have received eptinezumab infusion at the King Chulalongkorn Memorial Hospital (KCMH)
- Have received other CGRP mAbs prior to starting eptinezumab
- Able to communicate in Thai fluently
- Provide informed consent Group 1B
- <!-- -->
- Age ≥ 18 years
- Diagnosed with migraine with or without aura or chronic migraine according to the ICHD-3\*
- Have received eptinezumab infusion at the KCMH
- Have NEVER received any CGRP mAbs prior to starting eptinezumab
- Able to communicate in Thai fluently
- Provide informed consent
- \* The diagnosis will be established by consensus between two headache specialists. In case of a discrepancy, conflicts will be resolved through a final consensus agreement between the two specialists prior to enrollment.
- Group 2: Healthcare providers Inclusion criteria
- <!-- -->
- Age ≥ 18 years
- Currently working at KCMH
- Have been working at KCMH for more than 3 months
- Involved in providing care to patients attending the Headache Clinic
- Able to communicate in Thai fluently
- Provide informed consent
- Exclusion Criteria Group 1: People with migraine with or without aura or chronic migraine
- Participants who cannot completely participate in an in-depth interview (IDI) and questionnaires, either in-person or online
- Participants with headache disorders other than migraine with or without aura or chronic migraine
- Alcohol or drug use that, in the opinion of the investigator, would interfere with completion of study procedures
- A known history of allergy to eptinezumab Group 2: Healthcare providers
- <!-- -->
- Participants who cannot completely participate in an IDI, either in-person or online
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King Chualongkorn Memorial Hospital, the Thai Red Cross Society Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.